Skip to content

Oramed Pharmaceuticals

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for type 2 diabetes.

To contact GDPR Representative Services Limited, the UK representative of Oramed Pharmaceuticals, please email their dedicated inbox at